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effects. Meta-analysis of head-to-head comparisons represents a
robust method for anticipating the beneﬁt and risk of an emer-
gent statin, such as rosuvastatin, in comparison to an extensively
studied agent such as atorvastatin. METHODS: A systematic
literature search to identify head to head clinical studies of R and
A was conducted. Data were available for 30 comparisons of 1:1
dose ratios (R10mg vs. A10mg etc), 24 comparisons of 1:2 dose
ratios (R5mg vs. A10mg etc) and six comparisons of 1:4 dose
ratios (R5mg vs. A20mg etc). Treatment difference in beneﬁt (%
Low Density Lipoprotein-cholesterol [LDL-c] reduction) and
risk (odds ratios for myalgia, serious adverse events and with-
drawals due to adverse events, elevated Alaninaminotransferase
[ALT] (3xULN), and Creatine Kinase [CK] (>10xULN), were
estimated by meta-analysis (random effects) and presented in
beneﬁt risk planes. RESULTS: Analysis of 25 studies
(~24,000 pts) demonstrated rosuvastatin to be signiﬁcantly more
efﬁcacious than atorvastatin, for LDL-c reduction, at 1:1 and 1:2
dosage ratios. There were no signiﬁcant differences between
rosuvastatin and atorvastatin, at any dose ratio, for i) withdraw-
als due to adverse events, ii) myalgia, iii) serious adverse events,
iv) death, v) ALT > 3x upper limit of normal (ULN), and vi)
creatine kinase (CK) >10xULN. CONCLUSION: At 1:1 and 1:2
dose ratios, signiﬁcant additional reductions in LDL-c are
obtained by rosuvastatin at a comparable risk of the adverse
events presented.
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OBJECTIVE: To extend beyond the current approach of predict-
ing warfarin beneﬁt and harm independently in new atrial ﬁbril-
lation (AF) patients by reﬁning methods to identify predictors
of the four combined beneﬁt/harm outcome groups—i) no
stroke/no bleed; ii) no stroke/bleed; iii) stroke/bleed; iv) no
stroke/no bleed. METHODS: We analyzed patient-level data
from the Atrial Fibrillation Investigators RCT database
(n = 9155) and an observational database of AF patients
managed by Kaiser Permanente Colorado (n = 5475). We classi-
ﬁed patients based on the four beneﬁt/harm outcome groups and
applied decision tree modeling (CART) and polytomous logistic
regression (PLR) to identify patient factors predicting each
outcome group. Statistical signiﬁcance was set at alpha = 0.05.
RESULTS: CART and PLR consistently identiﬁed age and war-
farin use as predictors for all outcome groups. Both techniques
identiﬁed predictors of stroke/no bleed and no stroke/bleed not
previously included in AF stroke and bleed risk-assessment tools
that predict these outcomes independently (e.g., CHADS2 and
HEMORR2HAGES). Methodology strengths and limitations
were evident. CART provides a visual algorithm approach to
risk. However, there is a lack of quantitative measurement (e.g.,
odds ratios [OR], conﬁdence intervals) for predictors. While PLR
results were thorough and predictor parameter estimates could
be converted to ORs to indicate strength of association, the result
of PLR is number-intensive. To calculate a patient’s probability
for each of the four outcome groups, the patient’s data must be
inputted into three separate equations. While both techniques
can be used to calculate an individual patient’s probability for
each outcome group, PLR likely has more scope for application
in a clinical setting. Once reﬁned, a clinical prediction rule could
be created based on identiﬁed predictors and their ORs.
CONCLUSION: While methods under study need further reﬁne-
ment, these individual patient data analyses provide a useful step
forward in the movement towards evidence-based individualiza-
tion of drug therapy.
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OBJECTIVE: Angina is relieved by CABG, PCI and stenting
procedures but reoccurs over time in a percentage of patients.
Little is known about the frequency of recurrent angina follow-
ing percutaneous and surgical procedures, the characteristics
which put a patient at risk for recurrent angina and the timing
of angina recurrence. METHODS: Patients enrolled in a large
national managed care plan with a claim for a CABG, PCI or
stent from January 1, 2003 to Decemeber 31, 2004 were selected
if they were 35 or older, and enrolled one year prior and one year
following their procedure. Patients were followed for one year
after their index procedure for medication use, angina diagnosis
by ICD-9 code and additional revascularization procedures.
RESULTS: Following selection criteria 18,240 patients were eli-
gible for analysis. The average age was 59 years, with 25% age
65 years and older. Most patients were male (78%). Of the
18,240 patients, 46% (8420) experienced angina (identiﬁed
by angina diagnosis and/or two or more nitrate prescriptions)
within a year following their index procedure. Of those patients
experiencing angina, approximately a third (30%/2904) had
another revascularization procedure following the angina diag-
nosis. The average time from initial procedure to second proce-
dure, after angina diagnosis, was 73 days, although there is a
wide range among patients (SD = 103 days). Risk factors for
having angina following a revascularization procedure were
younger age, female gender and having a PCI without a stent.
CONCLUSION: Angina reoccurs in a considerable percentage of
patients in the year following a percutaneous or surgical coro-
nary procedure. A third of patients experiencing angina have a
second procedure after experiencing recurrent angina.
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OBJECTIVE: Resistant hypertension is deﬁned as the failure to
reach blood pressure (BP) goals while treated at adequate doses
with three or more antihypertensive agents (AHYs) where one is
a diuretic. Clinical trials have found that 2–15% of treated
patients have resistant hypertension. The exact prevalence of
resistant hypertension in clinical practice is unknown. This
analysis evaluates the prevalence of resistant hypertension in a
real-world setting. METHODS: Hypertensive patients aged 18
and older were identiﬁed from the General Electric Electronic
Medical Records (EMR) database during the period of Novem-
ber 1, 2002 to November 30, 2005. Resistant hypertension was
deﬁned as a blood pressure reading over 140/90 mmHg (130/
80 mmHg for patients with diabetes or kidney disease) within
one year after the last AHY agent was prescribed during a
treatment observation window of November 1, 2003 to Novem-
ber, 2004. RESULTS: A total of 29,474 hypertensive patients
were identiﬁed with an average age of 63.3 years (SD  13.3)
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and 60.9% were female. Of these 21,460 (72.8%) were treated
with at least one AHY and 3584 (12.2%) were treated with three
or more AHYs including a diuretic. Overall, 19,202 (65.6%) of
the population had uncontrolled hypertension, and 2670 (9.1%
overall or 12.4% of the treated population) had resistant hyper-
tension. Resistant hypertension occurred in 70.9% of those
treated with three AHYs including a diuretic and in 82.3% of
those treated with four or more AHYs including a diuretic. The
prevalence of diabetes and/or kidney disease was higher
in patients with resistant hypertension (37.8% vs. 22.9%;
p < 0.001). CONCLUSION: This study provides real-world evi-
dence that resistant hypertension is a common treatment concern
in the management of hypertension. Additional research to better
understand patient characteristics, long term outcomes, and
optimal treatment options in the management of resistant hyper-
tension is warranted.
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OBJECTIVE: The onset of cardiovascular diseases, such as an
acute myocardial infarction (AMI) shows certain circadian and
seasonal variation. The development of vascular diseases may
also be inﬂuenced by age and sex. The purpose of our study was
to ﬁnd out whether a weekly variation or a seasonal variation
could be found in the occurrence of a heart attack in the group
of women. METHODS: We have carried out a retrospective
analysis among women with the diagnosis of AMI (n = 32,345)
admitted to hospitals between 2000 and 2004 in Hungary,
grouped in age groups below and above the age of 50. Data was
collected from the data base of the National Health Insurance
Fund Administration according to the International Classiﬁca-
tion of Diseases (ICD I21, I22). RESULTS: With consideration
to seasonal variation, the peak period of AMI was during
Spring, with the lowest number of events during Summer
months. There was signiﬁcant difference between numbers of
events in each season (p < 0.01). The weekly peak period of AMI
morbidity was found on the ﬁrst day of the week, Monday;
showing a gradually decreasing tendency until the last day of the
week, Sunday (p < 0.01). No signiﬁcant difference was found
between the two age-groups regarding seasonal or weekly varia-
tion. CONCLUSION: In summary, the results of our study
suggest that AMI incidence in women shows a characteristic
variation regarding seasons and the days of the week, which
should be taken into consideration in the development of pro-
phylaxis strategies.
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OBJECTIVE: Numerous studies have reported the weekly
variation of an acute myocardial infarction. The Monday peek
has been connected with higher rate of physical and mental,
work-related stress. We wish to study the weekly variation of
an acute heart attack in the group of workers and pensioners,
and ﬁnd out whether National Holidays on the ﬁrst day of
the week inﬂuence the weekly rhythm of a heart attack.
METHODS: We have carried out the retrospective analysis of
patients received at Hungarian hospitals with the diagnose of
an acute heart attack (n = 88,687) between 2000 and 2005.
Data were retrieved from the data-base of the National Health
Insurance Fund in accordance with the International Classiﬁ-
cation of Diseases (ICD). RESULTS: According to the morbid-
ity data of a heart attack, the weekly peek is on the ﬁrst work-
day of the week, showing a gradually decreasing tendency until
the end of the week. Morbidity rates on Mondays being
National Holidays are similar to the number of events on Sat-
urdays and Sundays (Z = -25,337; p < 0.001). There was a sig-
niﬁcant difference between number of events on work-days and
weekends (Z = -26,638; p < 0.001). No marked difference has
been found between workers under the age of 65 and pension-
ers above the age of 65, or between the two sexes. CONCLU-
SION: The results of our study reveal that the occurrence
of an AMI shows characteristic changes through the days
of the week, and the ﬁrst work-days of the week may
be related with higher incidence of a heart attack. Such results
urge ﬁnding the potential new methods of forecast and
prevention.
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OBJECTIVES: To compare predicted coronary heart disease
(CHD) events and lipid goal attainment under the Framingham
and a managed care database risk equation in a managed care
patient cohort with established CHD. METHODS: Indepen-
dent outcomes models were developed from the Framingham-
based risk equation (FR model) and from a risk equation using
a large Integrated Research Database (IRD model). Prior
CHD patients 50 years (distribution based on NHANES
data) with combined sub-optimal LDL-C (100 mg/dL),
HDL-C (40 mg/dL, males; 50 mg/dL, females), and TG
levels (150 mg/dL) at baseline were modeled to predict CHD
events and lipid goals attained over ﬁve years. IRD model cova-
riates included age, gender, follow-up time, combined lipid goal
achievement, and Deyo-Charlson co-morbidity index. CHD
events included acute coronary syndrome, sudden coronary
artery disease death, and cardiac catheterization (PCI). Patient
therapy was based on a formulary with all major branded and
generic lipid drugs. RESULTS: Using a hypothetical 1,000,000
member plan, 35,059 patients aged 50 years were identiﬁed
with prior CHD. The percent of patients achieving LDL-C and
TG goals over ﬁve years was higher in the IRD model versus
FR model (68.9% vs. 62.7% and 69.9% vs. 49.2%, respec-
tively), while HDL-C goal achievement percent was comparable
(53.4% vs. 54.5%). The number of patients experiencing a
CHD event over ﬁve years was higher in the IRD versus FR
model (17,194 vs. 6387), reﬂecting the inclusion of actual prac-
tice CHD intervention (i.e., PCI) in unstable angina (14,430 vs.
1461). CONCLUSIONS: The established FR model appears to
conservatively underestimate both lipid response and theoreti-
cal CHD events, nor does it account for CHD clinical inter-
vention. The IRD model may better reﬂect the real world lipid
response and CHD events, also accounting for actual event
indicators of CHD intervention, being developed from a treat-
ment population.
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